Antipsychotics commonly used in the treatment of schizophrenia target dopamine receptors, but there is growing evidence that altered glutamate transmission is important in the pathophysiology of the disease. Researchers have developed a new drug, dubbed LY2140023, which is converted to a selective ...
“Schizophrenia is a leading cause of disability worldwide. It is a severe, chronic mental illness that is often damaging to a person’s quality of life,” said Dr. Tiffany Farchione, director of psychiatry in the Office of Neuroscience in the FDA’s Center for Drug Evaluation and Research....
The Promise of New Drugs for Schizophrenia Treatment To present aspects of preclinical and clinical pharmacology of new antipsychotic drugs and to emphasize those preclinical drug characteristics which might predict desirable clinical actions. Review of the relevant literature and publicly... Tamminga,Ca ...
A new drug to treat schizophrenia and depression has been approved by the U.S. Food and Drug Administration. Rexulti (brexpiprazole) tablets can be used to treat adults with schizophrenia. The new drug can also be used as an add-on therapy to antidepressant drugs for adults with major ...
DRUG targetSEROTONIN receptorsGABA receptorsGABA agonistsMYASTHENIA gravisSchizophrenia is a disease with a complex pathological mechanism that is influenced by multiple genes. The study of its pathogenesis is dominated by the dopamine hypothesis, as well as other hypotheses such as the 5-hy...
Schizophrenia is a devastating mental disease that affects the human population worldwide with an incidence of about 1%. Over the last decades basic and clinical research has considerably increased our understanding of the pathophysiology of schizophrenia, as well as the mechanism of action of antipsych...
Startling new impetus for schizophrenia researchSchizophreniaPrepulse inhibitionAntipsychotic drugsNo Abstractdoi:10.1016/S1359-6446(00)01564-6Kathryn SeniorElsevier LtdDrug Discovery Today
One of the researchers reporting that the finding is getting them closer to seeing what is going wrong in schizophrenia and what to target for drug treatment. And this understand of what is really going on, of what genes are involved and what they are doing is an important step for better...
BPDO-1603 is a potential cognitive-enhancing drug for AD, but its mechanism of action remains unknown [61]. A phase 3 trial of BPDO-1603 (NCT04229927) was started in February 2020 and is estimated to be completed in March 2023. The study has been undertaken to evaluate the efficacy and...
A US-based subsidiary of Japanese pharma giant Sumitomo is touting the mid-stage results of a schizophrenia drug they say offers a new way to treat the long-elusive disorder, potentially helping ...